查詢結果分析
相關文獻
- De novo CD5-positive Diffuse Large B-cell Lymphoma Presenting with Leg Edema
- CD5陽性B細胞
- Rituximab-induced Severe Pulmonary Disease
- Effect of Rituximab in Patients with Cyclophosphamide-non-responsive Connective Tissue Disease-Related Interstitial Lung Disease: A Case Series Study
- Rituximab Therapy in Chinese Patients with Lupus Nephritis
- 類風濕性關節炎應用生物製劑之病例探討
- Cytomegalovirus Infection in Non-transplant Patients with Hematologic Neoplasms: A Case Series
- Pneumocystis Jiroveci Pneumonia in Patients with Non-Hodgkin's Lymphoma Receiving Chemotherapy Containing Rituximab
- Risk Factor of Infusion-Related Reactions of Rituximab in Rheumatoid Arthritis: Single-Center Experience of 459 Infusions over 5 Years
- A Prospective Cohort Study of Patients with Chronic Hepatitis B (HBV) Infection with Rheumatic Diseases Receiving Rituximab
頁籤選單縮合
題 名 | De novo CD5-positive Diffuse Large B-cell Lymphoma Presenting with Leg Edema=以腳部水腫來表現之原發性CD5陽性濔漫性大B細胞淋巴瘤 |
---|---|
作 者 | 黃懷萱; 林中梧; 郭頌鑫; 鄭安理; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 28:3 2012.09[民101.09] |
頁 次 | 頁120-128 |
分類號 | 415.6 |
關鍵詞 | 濔漫性大B細胞淋巴瘤; CD5陽性; 莫須瘤; Diffuse large B-cell lymphoma; CD5-positive; Rituximab; |
語 文 | 英文(English) |
中文摘要 | 背景:濔漫性大 B 細胞淋巴瘤 (diffuse large B-cell lymphoma, DLBCL) 是最常見的非何杰 金氏淋巴瘤,且也是一個由多種疾病所組成的一群疾病。 案例描述:在此,我們報告一位罹患「原發性 CD5 陽性濔漫性大 B 細胞淋巴瘤」 (de novo CD5-positive DLBCL) 的病人,以右側骼骨附近、右側鼠蹊部附近、右側股骨附近、後腹 腔、及食道附近之淋巴結腫大來表現。其初期臨床特徵是以五個月內逐漸惡化的右側大 腿水腫為臨床表現。我們使用流式細胞儀,並合併組織病理學特殊染色來診斷原發性 CD5 陽性濔漫性大 B 細胞淋巴瘤。病人在接受三回合免疫化學治療 (immunochemotherpay of rituximab plus CEOP) 後達到完全緩解。然而,在完成六次免疫化學治療四個月後,病人 疾病復發並以大量右側胸水表現。同時,我們針對原發性 CD5 陽性濔漫性大 B 細胞淋巴 瘤的臨床表現及治療作文獻回顧和探討,並顯示它與其他濔漫性大 B 細胞淋巴瘤有著相 當程度的差異,並針對此疾病發展一適合治療策略。 結語:總而言之,原發性 CD5 陽性濔漫性大 B 細胞淋巴瘤是一群相當特殊的淋巴瘤,且 臨床病程較為侵犯性,預後較差。 |
英文摘要 | Background: Diffuse large B-cell lymphoma (DLBCL) is the most common of all non-Hodgkin’s lymphomas, and is also a heterogeneous disease. Case Description: Here, we report a case of de novo CD5-positive DLBCL of the right iliac, right inguinal, and right femoral with retroperitoneal and peri-esophageal involvement who was diagnosed not only by flow cytometric immunophenotyping but also by immunohistochemistry analyses. Initially, the patient presented with a complaint of progressive right leg edema for 5 months. Although complete remission was achieved after three cycles of immunochemotherapy (rituximab plus CEOP), relapse with a massive right side pleural effusion developed four months later, after a total of six cycles of immunochemotherapy were administered. We also reviewed the clinical manifestations and treatments for the disease, and highlighted the importance of identifying de novo CD5-positive DLBCL from other DLBCL, and of developing proper treatment strategies for this subgroup of patients. Conclusions: In conclusion, de novo CD5-positive DLBCL is a distinct group of DLBCL with aggressive courses of disease progress, with typically worse prognosis than DLBCL. |
本系統中英文摘要資訊取自各篇刊載內容。